 | • レポートコード：MRC2-11QY03881 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は重症筋無力症のグローバル市場について調査・分析したレポートです。種類別（医薬品、手術、造血幹細胞移植（HSCT）、血漿交換・静脈内）市場規模、用途別（病院、診療所、学術研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別重症筋無力症の競争状況、市場シェア ・世界の重症筋無力症市場：種類別市場規模 2015年-2020年（医薬品、手術、造血幹細胞移植（HSCT）、血漿交換・静脈内） ・世界の重症筋無力症市場：種類別市場規模予測 2021年-2026年（医薬品、手術、造血幹細胞移植（HSCT）、血漿交換・静脈内） ・世界の重症筋無力症市場：用途別市場規模 2015年-2020年（病院、診療所、学術研究所） ・世界の重症筋無力症市場：用途別市場規模予測 2021年-2026年（病院、診療所、学術研究所） ・北米の重症筋無力症市場分析：米国、カナダ ・ヨーロッパの重症筋無力症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの重症筋無力症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の重症筋無力症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの重症筋無力症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bausch Health、Sun Pharmaceuticals Industries、Novartis Pharmaceuticals、Teva Pharmaceutical Industries、Cipla、Roche、Apotex Corporation、Pfizer、Bristol-Myers And Company ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma.
Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmineand pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus gland may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.
Market Analysis and Insights: Global Myasthenia Gravis Disease Market
The global Myasthenia Gravis Disease market size is projected to reach US$ 980.9 million by 2026, from US$ 897.2 million in 2020, at a CAGR of 8.6%% during 2021-2026.
Global Myasthenia Gravis Disease Scope and Market Size
Myasthenia Gravis Disease market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bausch Health
Sun Pharmaceuticals Industries
Novartis Pharmaceuticals
Teva Pharmaceutical Industries
Cipla
Roche
Apotex Corporation
Pfizer
Bristol-Myers And Company
Market segment by Type, the product can be split into
Medication
Surgery
Hematopoietic Stem Cell Transplantation (HSCT)
Plasmapheresis And Intravenous
Market segment by Application, split into
Hospitals
Clinics
Academic Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myasthenia Gravis Disease Revenue
1.4 Market by Type
1.4.1 Global Myasthenia Gravis Disease Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medication
1.4.3 Surgery
1.4.4 Hematopoietic Stem Cell Transplantation (HSCT)
1.4.5 Plasmapheresis And Intravenous
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Disease Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Academic Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Market Perspective (2015-2026)
2.2 Global Myasthenia Gravis Disease Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myasthenia Gravis Disease Historic Market Share by Regions (2015-2020)
2.2.3 Myasthenia Gravis Disease Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myasthenia Gravis Disease Market Growth Strategy
2.3.6 Primary Interviews with Key Myasthenia Gravis Disease Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Players by Market Size
3.1.1 Global Top Myasthenia Gravis Disease Players by Revenue (2015-2020)
3.1.2 Global Myasthenia Gravis Disease Revenue Market Share by Players (2015-2020)
3.1.3 Global Myasthenia Gravis Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myasthenia Gravis Disease Market Concentration Ratio
3.2.1 Global Myasthenia Gravis Disease Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Revenue in 2019
3.3 Myasthenia Gravis Disease Key Players Head office and Area Served
3.4 Key Players Myasthenia Gravis Disease Product Solution and Service
3.5 Date of Enter into Myasthenia Gravis Disease Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myasthenia Gravis Disease Historic Market Size by Type (2015-2020)
4.2 Global Myasthenia Gravis Disease Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Myasthenia Gravis Disease Market Size by Application (2015-2020)
5.2 Global Myasthenia Gravis Disease Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myasthenia Gravis Disease Market Size (2015-2020)
6.2 Myasthenia Gravis Disease Key Players in North America (2019-2020)
6.3 North America Myasthenia Gravis Disease Market Size by Type (2015-2020)
6.4 North America Myasthenia Gravis Disease Market Size by Application (2015-2020)
7 Europe
7.1 Europe Myasthenia Gravis Disease Market Size (2015-2020)
7.2 Myasthenia Gravis Disease Key Players in Europe (2019-2020)
7.3 Europe Myasthenia Gravis Disease Market Size by Type (2015-2020)
7.4 Europe Myasthenia Gravis Disease Market Size by Application (2015-2020)
8 China
8.1 China Myasthenia Gravis Disease Market Size (2015-2020)
8.2 Myasthenia Gravis Disease Key Players in China (2019-2020)
8.3 China Myasthenia Gravis Disease Market Size by Type (2015-2020)
8.4 China Myasthenia Gravis Disease Market Size by Application (2015-2020)
9 Japan
9.1 Japan Myasthenia Gravis Disease Market Size (2015-2020)
9.2 Myasthenia Gravis Disease Key Players in Japan (2019-2020)
9.3 Japan Myasthenia Gravis Disease Market Size by Type (2015-2020)
9.4 Japan Myasthenia Gravis Disease Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Myasthenia Gravis Disease Market Size (2015-2020)
10.2 Myasthenia Gravis Disease Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myasthenia Gravis Disease Market Size by Type (2015-2020)
10.4 Southeast Asia Myasthenia Gravis Disease Market Size by Application (2015-2020)
11 India
11.1 India Myasthenia Gravis Disease Market Size (2015-2020)
11.2 Myasthenia Gravis Disease Key Players in India (2019-2020)
11.3 India Myasthenia Gravis Disease Market Size by Type (2015-2020)
11.4 India Myasthenia Gravis Disease Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Myasthenia Gravis Disease Market Size (2015-2020)
12.2 Myasthenia Gravis Disease Key Players in Central & South America (2019-2020)
12.3 Central & South America Myasthenia Gravis Disease Market Size by Type (2015-2020)
12.4 Central & South America Myasthenia Gravis Disease Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bausch Health
13.1.1 Bausch Health Company Details
13.1.2 Bausch Health Business Overview
13.1.3 Bausch Health Myasthenia Gravis Disease Introduction
13.1.4 Bausch Health Revenue in Myasthenia Gravis Disease Business (2015-2020))
13.1.5 Bausch Health Recent Development
13.2 Sun Pharmaceuticals Industries
13.2.1 Sun Pharmaceuticals Industries Company Details
13.2.2 Sun Pharmaceuticals Industries Business Overview
13.2.3 Sun Pharmaceuticals Industries Myasthenia Gravis Disease Introduction
13.2.4 Sun Pharmaceuticals Industries Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.2.5 Sun Pharmaceuticals Industries Recent Development
13.3 Novartis Pharmaceuticals
13.3.1 Novartis Pharmaceuticals Company Details
13.3.2 Novartis Pharmaceuticals Business Overview
13.3.3 Novartis Pharmaceuticals Myasthenia Gravis Disease Introduction
13.3.4 Novartis Pharmaceuticals Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.3.5 Novartis Pharmaceuticals Recent Development
13.4 Teva Pharmaceutical Industries
13.4.1 Teva Pharmaceutical Industries Company Details
13.4.2 Teva Pharmaceutical Industries Business Overview
13.4.3 Teva Pharmaceutical Industries Myasthenia Gravis Disease Introduction
13.4.4 Teva Pharmaceutical Industries Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.4.5 Teva Pharmaceutical Industries Recent Development
13.5 Cipla
13.5.1 Cipla Company Details
13.5.2 Cipla Business Overview
13.5.3 Cipla Myasthenia Gravis Disease Introduction
13.5.4 Cipla Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.5.5 Cipla Recent Development
13.6 Roche
13.6.1 Roche Company Details
13.6.2 Roche Business Overview
13.6.3 Roche Myasthenia Gravis Disease Introduction
13.6.4 Roche Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.6.5 Roche Recent Development
13.7 Apotex Corporation
13.7.1 Apotex Corporation Company Details
13.7.2 Apotex Corporation Business Overview
13.7.3 Apotex Corporation Myasthenia Gravis Disease Introduction
13.7.4 Apotex Corporation Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.7.5 Apotex Corporation Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Myasthenia Gravis Disease Introduction
13.8.4 Pfizer Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Bristol-Myers And Company
13.9.1 Bristol-Myers And Company Company Details
13.9.2 Bristol-Myers And Company Business Overview
13.9.3 Bristol-Myers And Company Myasthenia Gravis Disease Introduction
13.9.4 Bristol-Myers And Company Revenue in Myasthenia Gravis Disease Business (2015-2020)
13.9.5 Bristol-Myers And Company Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Myasthenia Gravis Disease Key Market Segments
Table 2. Key Players Covered: Ranking by Myasthenia Gravis Disease Revenue
Table 3. Ranking of Global Top Myasthenia Gravis Disease Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myasthenia Gravis Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Medication
Table 6. Key Players of Surgery
Table 7. Key Players of Hematopoietic Stem Cell Transplantation (HSCT)
Table 8. Key Players of Plasmapheresis And Intravenous
Table 9. Global Myasthenia Gravis Disease Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Myasthenia Gravis Disease Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Myasthenia Gravis Disease Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Myasthenia Gravis Disease Market Share by Regions (2015-2020)
Table 13. Global Myasthenia Gravis Disease Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Myasthenia Gravis Disease Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Myasthenia Gravis Disease Market Growth Strategy
Table 19. Main Points Interviewed from Key Myasthenia Gravis Disease Players
Table 20. Global Myasthenia Gravis Disease Revenue by Players (2015-2020) (Million US$)
Table 21. Global Myasthenia Gravis Disease Market Share by Players (2015-2020)
Table 22. Global Top Myasthenia Gravis Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease as of 2019)
Table 23. Global Myasthenia Gravis Disease by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Myasthenia Gravis Disease Product Solution and Service
Table 26. Date of Enter into Myasthenia Gravis Disease Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 29. Global Myasthenia Gravis Disease Market Size Share by Type (2015-2020)
Table 30. Global Myasthenia Gravis Disease Revenue Market Share by Type (2021-2026)
Table 31. Global Myasthenia Gravis Disease Market Size Share by Application (2015-2020)
Table 32. Global Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 33. Global Myasthenia Gravis Disease Market Size Share by Application (2021-2026)
Table 34. North America Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 36. North America Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 37. North America Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 38. North America Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 39. North America Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 40. Europe Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 42. Europe Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 44. Europe Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 46. China Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 47. China Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 48. China Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 49. China Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 50. China Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 51. China Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 52. Japan Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 54. Japan Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 56. Japan Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 60. Southeast Asia Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 62. Southeast Asia Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 64. India Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 65. India Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 66. India Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 67. India Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 68. India Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 69. India Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Myasthenia Gravis Disease Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Myasthenia Gravis Disease Market Share (2019-2020)
Table 72. Central & South America Myasthenia Gravis Disease Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Myasthenia Gravis Disease Market Share by Type (2015-2020)
Table 74. Central & South America Myasthenia Gravis Disease Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Myasthenia Gravis Disease Market Share by Application (2015-2020)
Table 76. Bausch Health Company Details
Table 77. Bausch Health Business Overview
Table 78. Bausch Health Product
Table 79. Bausch Health Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 80. Bausch Health Recent Development
Table 81. Sun Pharmaceuticals Industries Company Details
Table 82. Sun Pharmaceuticals Industries Business Overview
Table 83. Sun Pharmaceuticals Industries Product
Table 84. Sun Pharmaceuticals Industries Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 85. Sun Pharmaceuticals Industries Recent Development
Table 86. Novartis Pharmaceuticals Company Details
Table 87. Novartis Pharmaceuticals Business Overview
Table 88. Novartis Pharmaceuticals Product
Table 89. Novartis Pharmaceuticals Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 90. Novartis Pharmaceuticals Recent Development
Table 91. Teva Pharmaceutical Industries Company Details
Table 92. Teva Pharmaceutical Industries Business Overview
Table 93. Teva Pharmaceutical Industries Product
Table 94. Teva Pharmaceutical Industries Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 95. Teva Pharmaceutical Industries Recent Development
Table 96. Cipla Company Details
Table 97. Cipla Business Overview
Table 98. Cipla Product
Table 99. Cipla Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 100. Cipla Recent Development
Table 101. Roche Company Details
Table 102. Roche Business Overview
Table 103. Roche Product
Table 104. Roche Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 105. Roche Recent Development
Table 106. Apotex Corporation Company Details
Table 107. Apotex Corporation Business Overview
Table 108. Apotex Corporation Product
Table 109. Apotex Corporation Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 110. Apotex Corporation Recent Development
Table 111. Pfizer Business Overview
Table 112. Pfizer Product
Table 113. Pfizer Company Details
Table 114. Pfizer Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 115. Pfizer Recent Development
Table 116. Bristol-Myers And Company Company Details
Table 117. Bristol-Myers And Company Business Overview
Table 118. Bristol-Myers And Company Product
Table 119. Bristol-Myers And Company Revenue in Myasthenia Gravis Disease Business (2015-2020) (Million US$)
Table 120. Bristol-Myers And Company Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Market Share by Type: 2020 VS 2026
Figure 2. Medication Features
Figure 3. Surgery Features
Figure 4. Hematopoietic Stem Cell Transplantation (HSCT) Features
Figure 5. Plasmapheresis And Intravenous Features
Figure 6. Global Myasthenia Gravis Disease Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Academic Research Institutes Case Studies
Figure 10. Myasthenia Gravis Disease Report Years Considered
Figure 11. Global Myasthenia Gravis Disease Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Myasthenia Gravis Disease Market Share by Regions: 2020 VS 2026
Figure 13. Global Myasthenia Gravis Disease Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Myasthenia Gravis Disease Market Share by Players in 2019
Figure 16. Global Top Myasthenia Gravis Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Revenue in 2019
Figure 18. North America Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Myasthenia Gravis Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …- 重症筋無力症治療の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- 造血幹細胞移植（HSCT）の世界市場（～2026年） Market Analysis and Insights: Global Hematopoietic Stem Cell Transplantation (HSCT) Market The global Hematopoietic Stem Cell Transplantation (HSCT) market size is projected to reach US$ 16 million by 2026, from US$ 15 million in 2020, at a CAGR of 7.3%% during 2021-2026. Global Hematopoietic Stem C…
- クラッベ病治療の世界市場（～2026年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- レイノー病治療の世界市場（～2026年） Market Analysis and Insights: Global Raynauds Disease Treatment Market The global Raynauds Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Raynauds Disease Treatment Scope and Market Size Raynauds Dis…